In addition, pharmacological inhibition of CCR2 has been shown to reduce liver fibrosis in NASH [59], whereas CCR2 deficiency reduces macrophage aggregation and increases fibrosis [17,21]. Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.